Pinnacle Integrative Health

Social media got this completely wrong.

Faster escalation doesn't equal faster results. It equals receptor burnout.

When receptors are overstimulated too quickly:
- Excessive nausea
- Dysfunctional appetite suppression
- Reduced training capacity
- Fatigue and poor compliance
- Diminished long-term responsiveness

With a peptide this powerful, the goal is not to overwhelm the system. It's to guide adaptation.

Those are two very different things.

Most people think Retatrutide is a weight loss drug. The more interesting conversation is what happens after.

Growing clinical interest in low-dose maintenance:
- 0.1mg weekly
- Long-term metabolic support
- Not a weight loss tool at this stage

The goal shifts entirely:
- From: how much weight can we lose
- To: how do we preserve metabolic flexibility, insulin sensitivity, cardiovascular health, and body composition over decades

GLP-1. GIP. Glucagon receptor agonism. Three pathways. One molecule.
A longevity tool, not a trend.

That question changes everything.
Semaglutide hits one receptor. Tirzepatide hits two. Retatrutide hits three.

The third pathway, glucagon receptor agonism increases energy expenditure and fat mobilization simultaneously.

Phase 2 trial data, 48 weeks:
- 24% average weight reduction in higher dose groups

But the metabolic findings mattered more:
- Fasting glucose improved
- Insulin sensitivity restored
- Triglycerides down
- Blood pressure improved
- Liver fat markers reduced
- Visceral fat, significantly reduced

This isn't just weight loss data. This is metabolic restoration data.

Not a shopping list. Not one-size-fits-all. Not guesswork.

Right signals. Right sequence. Your biology.

Clients fly in from the East Coast for this. Because this level of precision doesn't exist anywhere else.

Join us at Ageless Future Seattle: https://agelessfutureseattle.com/event/